Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
Anti-CGRP ligand monoclonal antibody (2) ·
Antidepressant (1) ·
Anxiolytic (1) ·
Dual orexin receptor antagonist (DORA) (1) ·
SNRI (1) ·
the first approved (1) ·
[[:Category:Anesthetics|Anesthetic]] (1) ·
[[:Category:Antiarrhythmics|Antiarrhythmic (Vaughan Williams Class IB)]] (1) ·
[[:Category:Local anesthetics|Local anesthetic (amide class)]] (1)
mechanism:
None (1) ·
Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) ·
Humanized IgG1 monoclonal antibody binding CGRP peptide; IV infusion enables fastest onset of any CGRP mAb (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1)
uses:
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) ·
Preventive treatment of migraine in adults (1) ·
Preventive treatment of migraine in adults; episodic cluster headache (1) ·
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (1)
starting dose:
None (1) ·
10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) ·
100 mg IV every 3 months; may increase to 300 mg IV every 3 months (1) ·
Infiltration: 1-2% solution; '''4.5 mg/kg ceiling without epinephrine, 7 mg/kg with epinephrine'''. IV antiarrhythmic: 1-1.5 mg/kg bolus then infusion 1-4 mg/minute. Lidoderm patch: up to 3 patches per 12 hours (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)
preparations:
None (1) ·
100 mg/mL vial for IV infusion (1) ·
120 mg/mL prefilled syringe or autoinjector (1) ·
5 mg, 10 mg, 15 mg, 20 mg tablets (1) ·
Injection 0.5-4% solutions (with and without epinephrine); topical cream 4-5%; transdermal patch 5% (Lidoderm), 1.8% (ZTLido); oral 2% viscous solution; jelly 2%; ophthalmic (1)
fda max:
routes:
onset:
duration:
halflife: (Click arrow to add another value)
bioavailability:
pregnancy:
Error in "where" parameter: the string "--" cannot be used within #cargo_query.
There are no results for this report.